Top

Infection

Published in:

Open Access 14-06-2022 | First Degree Atrioventricular Block | Case Report

Remdesivir-induced bradycardia in a 26-year-old patient with COVID-19: a case report

Authors: Katarzyna Guziejko, Jaroslaw Talalaj, Monika Chorazy, Monika Groth, Anna Moniuszko-Malinowska

Published in: Infection | Issue 6/2022

Abstract

Purpose

Remdesivir is the first line hospital treatment of the SARS-CoV-2 infection. Despite its widespread use during COVID-19 pandemic, a limited number of data, also conflicting, are available about the frequency of cardiological side-effects. Additionally, identification of patients who belong to the risk groups for cardiovascular complications of antiviral treatment is difficult.

Case description

Case description We present a case of a 26 year old patient, a soldier with COVID-19 and no comorbidities, who developed marked sinus bradycardia during remdesivir therapy. The bradycardia resolved few days after the end of antiviral treatment.

Conclusion

Our case emphasizes the key importance of the correct monitoring of patients receiving remdesivir, even those who do not have pre-existing heart conditions.

Elshaboury RH, Monk MM, Bebell LM, Bidell MR, Adamsick ML, et al. Remdesivir use and outcomes during the FDA COVID-19 emergency use authorization period. Ther Adv Infect Dis. 2021. https://doi.org/10.1177/20499361211046669.CrossRefPubMedPubMedCentral

Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, et al. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci. 2020;6:672–83. https://doi.org/10.1021/acscentsci.0c00489.CrossRefPubMedPubMedCentral

Jorgensen SCJ, Kebriaei R, Dresser LD. Remdesivir: review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19. Pharmacotherapy. 2020;40:659–71. https://doi.org/10.1002/phar.2429.CrossRefPubMedPubMedCentral

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, et al. Compassionate use of remdesivir for patients with severe covid-19. N Engl J Med. 2020;382:2327–36. https://doi.org/10.1056/NEJMoa2007016.CrossRefPubMed

Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, GS-US-540–5773 Investigators, et al. Remdesivir for 5 or 10 days in patients with severe covid-19. N Engl J Med. 2020;383:1827–37. https://doi.org/10.1056/NEJMoa2015301.CrossRefPubMed

Humeniuk R, Mathias A, Cao H, Osinusi A, Shen G, et al. Safety, tolerability, and pharmacokinetics of remdesivir, an antiviral for treatment of COVID-19 healthy subjects. Clin Transl Sci. 2020;13:896–906. https://doi.org/10.1111/cts.12840.CrossRefPubMedPubMedCentral

Elsawah HK, Elsokary MA, Abdallah MS, ElShafie AH. Efficacy and safety of remdesivir in hospitalized Covid-19 patients: Systematic review and meta-analysis including network meta-analysis. Rev Med Virol. 2021;31: e2187. https://doi.org/10.1002/rmv.2187.CrossRefPubMed

Choi SW, Shin JS, Park SJ, Jung E, Park YG, et al. Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes. Antiviral Res. 2020;184: 104955. https://doi.org/10.1016/j.antiviral.2020.104955.CrossRefPubMedPubMedCentral

Nabati M, Parsaee H. Potential cardiotoxic effects of remdesivir on cardiovascular system: a literature review. Cardiovasc Toxicol. 2021;13:1–5. https://doi.org/10.1007/s12012-021-09703-9.CrossRef

10.

Bistrovic P, Lucijanic M. Remdesivir might induce changes in electrocardiogram beyond bradycardia in patients with coronavirus disease 2019-The pilot study. J Med Virol. 2021;93:5724–5. https://doi.org/10.1002/jmv.27177.CrossRefPubMedPubMedCentral

11.

Jung SY, Kim MS, Li H, Lee KH, Koyanagi A, et al. Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database. Clin Transl Sci. 2022;15:501–13. https://doi.org/10.1111/cts.13168.CrossRefPubMed

12.

Brunetti ND, Poliseno M, Bottalico IF, Centola A, Montemurro L, et al. Safety and heart rate changes in Covid-19 patients treated with remdesivir. Int J Infect Dis. 2021;112:254–7. https://doi.org/10.1016/j.ijid.2021.09.036.CrossRefPubMedPubMedCentral

13.

Gupte V, Hegde R, Sawant S, Kalathingal K, Jadhav S, et al. Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients: a retrospective analysis of active surveillance database. BMC Infect Dis. 2022;22:1. https://doi.org/10.1186/s12879-021-07004-8.CrossRefPubMedPubMedCentral

14.

Wang Y, Zhang D, Du G, Du R, Zhao J, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569–78. https://doi.org/10.1016/S0140-6736(20)31022-9.CrossRefPubMedPubMedCentral

15.

Touafchia A, Bagheri H, Carrié D, Durrieu G, Sommet A, et al. Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns. Clin Microbiol Infect. 2021;27:791.e5-8. https://doi.org/10.1016/j.cmi.2021.02.013.CrossRefPubMed

16.

Bistrovic P, Manola S, Lucijanic M. Bradycardia during remdesivir treatment might be associated with improved survival in patients with COVID-19: a retrospective cohort study on 473 patients from a tertiary centre. Postgrad Med J. 2021. https://doi.org/10.1136/postgradmedj-2021-141079.CrossRefPubMed

17.

Attena E, Albani S, Maraolo AE, Mollica M, De Rosa A, et al. Remdesivir-Induced Bradycardia in COVID-19: a single center prospective study. Circ Arrhythm Electrophysiol. 2021;14: e009811. https://doi.org/10.1161/CIRCEP.121.009811.CrossRefPubMedPubMedCentral

18.

Ching PR, Lee C. Remdesivir-associated bradycardia. BMJ Case Rep. 2021;14: e245289. https://doi.org/10.1136/bcr-2021-245289.CrossRefPubMedPubMedCentral

19.

Gubitosa JC, Kakar P, Gerula C, Nossa H, Finkel D, et al. Marked sinus bradycardia associated with remdesivir in COVID-19: a case and literature review. JACC Case Rep. 2020;2:2260–4. https://doi.org/10.1016/j.jaccas.2020.08.025.CrossRefPubMedPubMedCentral

20.

Elikowski W, Fertala N, Zawodna-Marszalek M, Rajewska-Tabor J, Swidurski W, et al. Marked self-limiting sinus bradycardia in COVID-19 patients not requiring therapy in the intensive care unit - case series report. Pol Merkur Lekarski. 2021;49:295–302.PubMed

21.

Jacinto JP, Patel M, Goh J, Yamamura K. Remdesivir-induced symptomatic bradycardia in the treatment of COVID-19 disease. HeartRhythm Case Rep. 2021;7:514–7. https://doi.org/10.1016/j.hrcr.2021.05.004.CrossRefPubMedPubMedCentral

22.

Shirvani M, Sayad B, Shojaei L, Amini A, Shahbazi F. Remdesivir-associated significant bradycardia: a report of three cases. J Tehran Heart Cent. 2021;16:79–83. https://doi.org/10.18502/jthc.v16i2.7390.CrossRefPubMedPubMedCentral

23.

Badgujar KC, Ram AH, Zanznay R, Kadam H, Badgujar VC. Remdesivir for COVID-19: a review of pharmacology, mechanism of action, in-vitro activity and clinical use based on available case studies. J Drug Delivery Ther. 2020;10:264–70. https://doi.org/10.22270/jddt.v10i4-s.4313.CrossRef

24.

Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond). 2021;53:737–54. https://doi.org/10.1080/23744235.2021.1924397.CrossRefPubMed

25.

Azevedo RB, Botelho BG, Hollanda JVG, et al. Covid-19 and the cardiovascular system: a comprehensive review. J Hum Hypertens. 2021;35:4–11. https://doi.org/10.1038/s41371-020-0387-4.CrossRefPubMed

26.

Liu Q, Chen H, Zeng Q. Clinical characteristics of COVID-19 patients with complication of cardiac arrhythmia. J Infect. 2020;81:e6–8. https://doi.org/10.1016/j.jinf.2020.07.012.CrossRefPubMedPubMedCentral

Title: Remdesivir-induced bradycardia in a 26-year-old patient with COVID-19: a case report
Authors: Katarzyna Guziejko
Jaroslaw Talalaj
Monika Chorazy
Monika Groth
Anna Moniuszko-Malinowska
Publication date: 14-06-2022
Publisher: Springer Berlin Heidelberg
Keywords: First Degree Atrioventricular Block
SARS-CoV-2
COVID-19
Published in: Infection / Issue 6/2022
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI: https://doi.org/10.1007/s15010-022-01854-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Case description

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2022

Enterococcus faecalis bacteremia, cardiac implantable electronic device, extraction, and the risk of recurrence

Myelitis with flaccid paralysis due to Japanese encephalitis: case report and review of the literature

Cytomegalovirus infection and rehospitalization rates after allogeneic hematopoietic stem cell and solid organ transplantation: a retrospective cohort study using German claims data

Hepatitis D virus infection in a large cohort of immigrants in southern Italy: a multicenter, prospective study

Tularemia research activity: a bibliometric analysis between 1980 and 2020

Asymptomatic bacteriospermia and infertility—what is the connection?

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials